Somalogic, Incorporated

Gilead Sciences, Inc.

Somalogic Operating Co., Inc.

Daniel W Drolet

Chi Zhang

Nebojsa Janjic

Amy D Gelinas

Larry M Gold

John C Rohloff

Thale Jarvis

Sheela M Waugh

Michael Vrkljan

Sumedha D Jayasena

Dominic Zichi

Stanley C Gill

Shashi Gupta

Steve Creighton

Daniel J O'Connell

Thale C Jarvis

Daniel J O'connell

Described herein are aptamers capable of binding to human complement component 3 (C3) protein; compositions comprising a C3 binding aptamer with a C3-Protein; and methods of making and using the same.

Nucleic acid compounds for binding to complement component 3 protein

Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.

Post-selex modification methods

Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.

PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders

Post-selec modification methods

Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions

Methods are described for the identification and preparation of nucleic acid ligands to calf intestinal phosphatase. Included in the invention are specific RNA ligands to calf intestinal phosphatase identified by the SELEX method.

2&prime;-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands

A diagnostic biochip comprising a solid support to which one or more specific nucleic acid ligands is attached in a spatially defined manner is provided. Each nucleic acid ligand binds specifically and avidly to a particular target molecule contained within a test mixture, such as a bodily fluid. Also provided are methods for the preparation of nucleic acid ligand biochips. Further, methods for the use of the nucleic acid ligand biochip in diagnosis of a medical condition and quantitative detection of a target molecule are provided.

Nucleic acid ligand diagnostic biochip

Growing community of inventors

Boulder, CO, United States of America

Daniel W Drolet